Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

548.05
+7.791.44%
Post-market: 548.050.00000.00%19:52 EDT
Volume:1.07M
Turnover:589.66M
Market Cap:139.05B
PE:31.90
High:555.32
Open:545.10
Low:540.70
Close:540.26
52wk High:555.32
52wk Low:374.17
Shares:253.72M
Float Shares:253.72M
Volume Ratio:0.86
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):17.18
EPS(LYR):15.32
ROE:23.54%
ROA:11.93%
PB:6.87
PE(LYR):35.77

Loading ...

U.S. Earnings Preview: After Market Close Aug. 3

Dow Jones
·
Aug 04

Vertex options imply 5.4% move in share price post-earnings

TIPRANKS
·
Aug 04

3 US Stocks Built For Tariff Driven Supply Chain Shifts

Simply Wall St.
·
Aug 03

Tyson Foods, Marriott And 3 Stocks To Watch Heading Into Monday

Benzinga Earnings
·
Aug 03

Vertex Minerals Director Increases Stake via Share Purchase Plan

TIPRANKS
·
Aug 03

Vertex Minerals Director Lifts Stake and Supports Financing via Convertible Loan

TIPRANKS
·
Aug 03

Vertex Minerals Seeks Quotation for 8.58 Million New Shares

TIPRANKS
·
Aug 03

Vertex Minerals bolsters balance sheet with successful share purchase plan

TIPRANKS
·
Aug 03

Vertex Minerals prioritises Reward mine development as funding and recoveries strengthen

TIPRANKS
·
Jul 31

New Vertex Research Signals a Turning Point for Indirect Tax and Compliance: The Rise of Decision-to-Defense

GlobeNewswire
·
Jul 30

AbCellera and Vertex launch autoimmune T-cell engager partnership

TIPRANKS
·
Jul 30

Abcellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

THOMSON REUTERS
·
Jul 29

Abcellera Biologics - Vertex to Fund All R&D and Commercialize Antibodies from Collaboration

THOMSON REUTERS
·
Jul 29

Abcellera Biologics - Abccellera to Receive $28 Mln Upfront Plus Milestone Payments and Tiered Royalties

THOMSON REUTERS
·
Jul 29

Vertex Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 29

Analysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (BMRN), Zoetis (ZTS) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jul 28

Crinetics downgraded to Neutral from Buy at UBS

TIPRANKS
·
Jul 28

Earning Preview: Vertex Pharmaceuticals this quarter’s revenue is expected to increase by 11.23%, and institutional views are bullish

Earnings Agent
·
Jul 27

Vertex Minerals appoints independent expert after multiple ASX Listing Rule breaches

TIPRANKS
·
Jul 23

Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Jul 23